valdecoxib
Sign in to saveAlso known as Bextra®, SC-65872, 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide, p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide
Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. It was patented in 1995.
Research
586 papers- Valdecoxib.2006
- Valdecoxib.Drugs · 2002
- Valdecoxib: a review.Clinical therapeutics · 2003
- Valdecoxib.Reviews in gastroenterological disorders · 2002
- [Valdecoxib (Bextra)].Revue medicale de Liege · 2004
via PubMed
~5 min read
Encyclopedic overview
7 sectionsContents
- Uses until 2005
- Side effects and withdrawal from market
- 2009 settlement for off-label uses promotions
- Analytical methods
- See also
- References
- External links
Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. It was patented in 1995.
Valdecoxib was manufactured and marketed under the brand name Bextra by G. D. Searle & Company as an anti-inflammatory arthritis drug. It was approved by the United States Food and Drug Administration (FDA) on November 20, 2001, to treat arthritis and menstrual cramps, and was available by prescription in tablet form until 2005 when the FDA requested that Pfizer (Searle's parent company) withdraw Bextra from the American market. The FDA cited "potential increased risk for serious cardiovascular (CV) adverse events," an "increased risk of serious skin reactions" and the "fact that Bextra has not been shown to offer any unique advantages over the other available NSAIDs."
Excerpted from Wikipedia’s “valdecoxib” article, available under the CC BY-SA 4.0 licence.